The race to market genetic testing directly to consumers has begun, with little fanfare and even less discussion about many of the accuracy, efficacy or patient privacy issues facing a nascent biotechnology with unprecedented potential to change our lives…
Filed under: NerveCenter | Tagged: 23andMe, Affymetrix, ALS, alzheimer, Charcot-Marie-Tooth, DeCode Genetics, deCODEme, dementia, direct to consumer, disease screening, Duchenne muscular dystrophy, genetic disease, genetic testing, genetics, genomics, genotype, genotyping, Huntington's disease, inheritable disease, microarray DNA scan, Multiple Sclerosis, Navigenics, Parkinson, patient privacy, Perlegen | Leave a Comment »
